Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Regina Horneff

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|August 29, 2024
Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial ApprovalRegina Horneff, Barbara Czech, Michael Yeh, et al.
International Journal of Molecular Sciences|September 14, 2024
Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement InhibitorsPeter Hillmen, Regina Horneff, Michael Yeh, et al.
Mitochondrion|January 29, 2018
Phosphorylation of the outer membrane mitochondrial protein OM64 influences protein import into mitochondriaCatharina Nickel, Regina Horneff, Ralf Heermann, et al.
Research and Practice in Thrombosis and Haemostasis|May 30, 2024
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settingsRichard J Kelly, Hisakazu Nishimori, Regina Horneff, et al.
European Journal of Haematology|March 25, 2023
Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial dataJens Panse, Koo Wilson, Jesse Fishman, et al.
International Journal of Molecular Sciences|August 29, 2024
Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow FunctionJeff Szer, Jens Panse, Austin Kulasekararaj, et al.
Blood Advances|April 9, 2024
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuriaRégis Peffault de Latour, Morag Griffin, Richard J Kelly, et al.
Blood Advances|February 5, 2024
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNHMorag Griffin, Richard J Kelly, Jens Panse, et al.
Nephron|September 19, 2025
Clinical Presentation, Treatment Patterns, Burden of Disease, and the Association of Proteinuria with Clinical Outcomes in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic ReviewFernando Caravaca-Fontán, Fadi Fakhouri, Matthew C Pickering, et al.
European Journal of Haematology|November 23, 2023
Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivityKoo Wilson, Carly Rich, Zalmai Hakimi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|August 29, 2024
Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial ApprovalRegina Horneff, Barbara Czech, Michael Yeh, et al.
International Journal of Molecular Sciences|September 14, 2024
Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement InhibitorsPeter Hillmen, Regina Horneff, Michael Yeh, et al.
Mitochondrion|January 29, 2018
Phosphorylation of the outer membrane mitochondrial protein OM64 influences protein import into mitochondriaCatharina Nickel, Regina Horneff, Ralf Heermann, et al.
Research and Practice in Thrombosis and Haemostasis|May 30, 2024
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settingsRichard J Kelly, Hisakazu Nishimori, Regina Horneff, et al.
European Journal of Haematology|March 25, 2023
Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial dataJens Panse, Koo Wilson, Jesse Fishman, et al.
International Journal of Molecular Sciences|August 29, 2024
Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow FunctionJeff Szer, Jens Panse, Austin Kulasekararaj, et al.
Blood Advances|April 9, 2024
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuriaRégis Peffault de Latour, Morag Griffin, Richard J Kelly, et al.
Blood Advances|February 5, 2024
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNHMorag Griffin, Richard J Kelly, Jens Panse, et al.
Nephron|September 19, 2025
Clinical Presentation, Treatment Patterns, Burden of Disease, and the Association of Proteinuria with Clinical Outcomes in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic ReviewFernando Caravaca-Fontán, Fadi Fakhouri, Matthew C Pickering, et al.
European Journal of Haematology|November 23, 2023
Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivityKoo Wilson, Carly Rich, Zalmai Hakimi, et al.
Pageof 2